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IMPORTANCE It is uncertain to what extent established cardiovascular risk factors are
associated with venous thromboembolism (VTE).
OBJECTIVE To estimate the associations of major cardiovascular risk factors with VTE, ie,
deep vein thrombosis and pulmonary embolism.
DESIGN, SETTING, AND PARTICIPANTS This study included individual participant datamostly
from essentially population-based cohort studies from the Emerging Risk Factors
Collaboration (ERFC; 731 728 participants; 75 cohorts; years of baseline surveys, February
1960 to June 2008; latest date of follow-up, December 2015) and the UK Biobank (421 537
participants; years of baseline surveys, March 2006 to September 2010; latest date of
follow-up, February 2016). Participants without cardiovascular disease at baseline were
included. Data were analyzed from June 2017 to September 2018.
EXPOSURES A panel of several established cardiovascular risk factors.
MAINOUTCOMES ANDMEASURES Hazard ratios (HRs) per 1-SDhigher usual risk factor levels (or
presence/absence). Incident fatal outcomes in ERFC (VTE, 1041; coronary heart disease [CHD],
25 131) and incident fatal/nonfatal outcomes inUKBiobank (VTE, 2321; CHD, 3385). Hazard ratios
were adjusted for age, sex, smoking status, diabetes, and bodymass index (BMI).
RESULTS Of the 731 728 participants from the ERFC, 403 396 (55.1%) were female, and the
mean (SD) age at the time of the survey was 51.9 (9.0) years; of the 421 537 participants from
the UK Biobank, 233 699 (55.4%) were female, and themean (SD) age at the time of the
survey was 56.4 (8.1) years. Risk factors for VTE included older age (ERFC: HR per decade,
2.67; 95% CI, 2.45-2.91; UK Biobank: HR, 1.81; 95% CI, 1.71-1.92), current smoking (ERFC: HR,
1.38; 95% CI, 1.20-1.58; UK Biobank: HR, 1.23; 95% CI, 1.08-1.40), and BMI (ERFC: HR per 1-SD
higher BMI, 1.43; 95% CI, 1.35-1.50; UK Biobank: HR, 1.37; 95% CI, 1.32-1.41). For these factors,
there were similar HRs for pulmonary embolism and deep vein thrombosis in UK Biobank
(except adiposity was more strongly associated with pulmonary embolism) and similar HRs
for unprovoked vs provoked VTE. Apart from adiposity, these risk factors were less strongly
associated with VTE than CHD. There were inconsistent associations of VTEs with diabetes
and blood pressure across ERFC and UK Biobank, and there was limited ability to study lipid
and inflammationmarkers.
CONCLUSIONS AND RELEVANCE Older age, smoking, and adiposity were consistently
associated with higher VTE risk.
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V enous thromboembolism(VTE), consistingofdeepveinthrombosis (DVT)orpulmonaryembolism(PE), is ama-jor clinical burden. Globally, there are about 10million
cases every year, and it is the third leading vascular disease af-
ter myocardial infarction and stroke.1 Pulmonary embolism is
amanifestationofVTEand is responsible formostVTEdeaths.2
In recentyears, efforts topreventVTEhavebroadened fromfo-
cusingmainlyonhospital-basedriskfactors (eg, recentpriorsur-
gery, cancer, and congestive heart failure) toward adoption of
heart-healthy lifestyles.3 This perspective has challenged tra-
ditional viewsofvenousandarterial thrombosis asdistinctpa-
thologies, encouraging prevention strategies that concomi-
tantly address VTE and arterial thrombosis.2,4 However, there
is uncertainty about the extent to which venous and arterial
thrombosis sharecardiovascular risk factors, as studieshavere-
portedconflicting findings.5-15 Interpretationhasbeencompli-
cated by the use of retrospective case-control designs, limited
statistical power, and/or inability to compare VTE and arterial
disease outcomes within the same cohorts.16-26
Analyzing data frommore than 1.1 million participants in
76 prospective studies, we investigated associations of sev-
eral established cardiovascular risk factors with the inci-
denceofVTEoutcomes.Weaimed toaddress2principal ques-
tions: What are the associations of major cardiovascular risk
factorswithVTEoutcomes (includingsubtypes)?Howdothese
associations compare with those for coronary heart disease
(CHD), a manifestation of arterial thrombotic disease?
Methods
Data Sources and Participant Inclusion
We analyzed data from the Emerging Risk Factors Collabora-
tion (ERFC), a consortium of prospective cohort studies with
information on a variety of risk factors, and the UK Biobank,
a single large prospective study. Both the ERFC and UK Bio-
bank have been described previously.27,28 Both data sources
involve a prospective cohort study design and accessible in-
dividual participant data, enabling standardized and de-
tailed analyses using a common protocol, including defini-
tions for VTE and CHD outcomes. However, we conducted
parallel (rather than pooled) analyses of the 2 sources be-
cause of potentially important differences in their ap-
proaches toVTEascertainment, ie, theERFC recordedonly fa-
tal VTE outcomes while UK Biobank recorded both fatal and
nonfatal VTE outcomes, most of which were nonfatal. Infor-
mation about eachof the 76 studies contributing to this analy-
sis is provided in the eAppendix in theSupplement. The study
wasdesignedandconductedby theEmergingRiskFactorsCol-
laboration academic coordinating center, and it was ap-
proved by the Cambridgeshire Ethics Review Committee. In-
formed consentwas obtained fromparticipants in eachof the
cohorts contributing to the analysis.
Participants in thecontributing studieswereeligible for in-
clusion in the current analysis if they met all of the following
criteria: (1)hadrecorded informationonseveralestablishedcar-
diovascular risk factors (asaminimum, informationonage, sex,
smokingstatus,historyofdiabetes,andbodymass index[BMI]),
(2)didnothaveaknownbaselinehistoryof cardiovasculardis-
ease (CVD; defined as CHD, other heart disease, stroke, tran-
sient ischemic attack, peripheral vascular disease, or cardio-
vascular surgery) or VTE (defined as DVT or PE), and (3) had at
least 1 year of follow-up data after baseline.
IntheERFC,onlyfatalVTEeventswererecorded.Ascertain-
mentwasbasedondeathcertificates supplemented in56stud-
ies bymedical records, findingsonautopsy, andother sources.
InUKBiobank,fatalandnonfatalVTEswereascertainedthrough
linkagewith routinelycollectedmedical records.Weattempted
tosubcategorizeVTEsasprovokedandunprovokedusingaprag-
matic approach that required inference from routine records
(eAppendix in theSupplement).Briefly, following theexample
ofpreviouswork,13wedefinedVTEasprovokedif, in the90-day
periodpreceding theVTE, theparticipantwas recordedashav-
ingamalignantneoplasm(per cancer registrydata); startingor
endingahospital episodewithamaindiagnosis coderelating to
malignantneoplasm,heart failure, infectiousdisease,ortrauma;
or having a hospital episode that included certain types of sur-
gical procedures. The specific International Statistical Classifi-
cation ofDiseases andRelatedHealth Problems (ICD) codes and
Classificationof InterventionsandProcedures codes that are in-
cludedinourdefinitionaresummarized intheeAppendix inthe
Supplement.All studiesuseddefinitionsofCHDbasedonWorld
HealthOrganization (or similar) criteria. In registering fatalout-
comes,thecontributingstudiesclassifieddeathsaccordingtothe
primary cause (or, in its absence, the underlying cause) on the
basis of ICD-8, ICD-9, and ICD-10 codes to at least 3digits or ac-
cording to study-specific classification systems. In the ERFC,
baseline surveys were given between February 1960 and June
2008,and thedateof latest follow-upwasDecember2015 (me-
dian, 2014across studies); in theUKBiobank, baseline surveys
weregivenbetweenMarch2006andSeptember2010, and the
date of latest follow-upwas February 2016.
Statistical Analysis
Forcontinuousriskfactors,wecalculatedhazardratios (HRs)per
1-SDhigherusualriskfactor level.Forbinaryriskfactors,wecom-
pared presence vs absence of the factor. Cox proportional haz-
ards regressionmodels were adjusted for age, smoking status,
history of diabetes, and BMI and stratified by study, sex, and
(when appropriate) trial arm. To avoid overadjustment, we did
not routinelyadjust forsystolicbloodpressureor lipidmeasure-
ments (which, for example, can mediate the effects of adipos-
ity). Similarly, we did not adjust for BMI when analyzing other
Key Points
Question To what extent are established cardiovascular risk
factors associated with risk of venous thromboembolism (VTE)?
Findings In this analysis of individual participant data from the
Emerging Risk Factors Collaboration and the UK Biobank including
1.1 million participants, among a panel of several established
cardiovascular risk factors, older age, smoking, and greater
adiposity were consistently associated with higher VTE risk.
Meaning There is overlap in at least someof themajor population
determinants of important venous and arterial thrombotic diseases.
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measuresofadiposity (eg,waist circumference).Participants in
theUKBiobankwerecensoredatfirstnonfatalCVDevent,death,
orstudyexit,whicheveroccurredfirst.Participants inERFCwere
censored at death or study exit. Because nonfatal CVDmay re-
sult in hospitalization (which may, in turn, lead to VTE out-
comes), sensitivity analyses additionally censored at the first
nonfatal CVD event in ERFC.
Tocorrect forregressiondilutioncausedbyvariability in lev-
elsofcontinuousrisk factors,weregressedserialmeasurements
of risk factors obtained fromup to 146749participants inERFC
(meaninterval,8.4years)andupto24235participants inUKBio-
bank(mean interval, 5.2years)onbaseline levelsof therelevant
characteristics.Correctionforwithin-personvariationinriskfac-
torswasachievedbyuseofconditionalexpectationsof long-term
averagelevels (termedusual levels)oftheriskfactors,whichwere
predictedfromregressioncalibrationmodelsandusedinestima-
tion ofHRs, as described previously.29
Tocharacterizeshapesofassociations,HRscalculatedwithin
overall fifths of baseline exposure values were plotted against
mean usual values of the relevant risk factor within each
fifth. We used the Plummer method to estimate 95% CIs from
the variances that corresponded to the amount of information
underlying each group (including the reference category).30
Because a further aim of the study was to compare asso-
ciations of risk factors with VTE vs CHD outcomeswithin the
same cohorts,we defined a competing riskmodel using a rec-
ord duplication approach, allowing for simultaneous cause-
specific hazard regression to estimate cause-specific HRs for
each type of event. In ERFC, we stratified the cause-specific
regressionmodelbycohort toallowforadifferentbaselinehaz-
ard function in each study. We tested for differences in asso-
ciations with VTE vs CHD based on the interaction between
eachexposurevariable and theevent type indicator variable.31
Analyses were carried out in Stata version 13 (StataCorp).
Because of the number of statistical tests done, principal em-
phasiswas given to findingswith aP value less than .001, and
all P values were 2-sided.
Results
Data were available for 731 728 participants from 75 ERFC co-
horts and 421 537 participants from UK Biobank (Table)
(eTable 1 in the Supplement). The mean (SD) age at baseline
was 51.9 (9.0) years in ERFC and 56.4 (8.1) years in UK Bio-
bank; 403 396 participants (55.1%) in the ERFC and 233699
(55.4%) inUKBiobankwere female.Mostparticipants inERFC
were enrolled in either Europe (369 757 of 731 728 [50.5%]) or
North America (315 278 of 731 728 [43.1%]). During a median
follow-up of 15.4 years, 1041 fatal VTE events and 25 131 fatal
CHD events were recorded in the ERFC. In UK Biobank, 2321
fatal or nonfatal VTE events and 3385 fatal or nonfatal CHD
events were recorded during amedian follow-up of 6.1 years.
Associationsof several risk factorswithVTEwereapproxi-
mately log-linear (Figure1).Olderagewasassociatedwithhigher
risk of VTE,with an approximately 2.8-fold higher risk per de-
cade inERFCand1.8-foldhigher riskperdecade inUKBiobank
(Figure2).Comparedwithfemales,maleshadahigherriskofVTE
inUKBiobank (HR, 1.44;95%CI, 1.32-1.56), somewhat less so in
ERFC(HR, 1.17;95%CI,0.998-1.38).Current smokingwasasso-
ciatedwith VTE risk in ERFC (HR, 1.38; 95% CI, 1.20-1.58), but
somewhat less so in UK Biobank (HR, 1.23; 95% CI, 1.08-1.40).
Markersofadiposity (BMI,waist-to-hip ratio, andwaist circum-
ference)werepositivelyassociatedwithhigherVTErisk inboth
ERFC and UK Biobank. For example, HRs per 1-SD higher BMI
were 1.43 (95%CI, 1.35-1.50) inERFCand1.37 (95%CI, 1.32-1.41)
inUKBiobank. Current alcohol consumptionwas inversely as-
sociatedwithVTErisk inbothERFC(HR,0.75;95%CI,0.61-0.93)
and UK Biobank (HR, 0.82; 95% CI, 0.71-0.94). In exploratory
analyses restricted to current drinkers in UK Biobank (which
should limit theeffectsofcertainresidualbiases, suchasreverse
causality relatedtosickquitters32),wefoundthat the inverseas-
sociationbetweenamountofalcoholconsumedandVTEriskper-
sisted (eFigure 1 in the Supplement).
Bycontrast, forsomeotherriskfactorswestudied,wenoted
potentiallydirectionallydiscordantassociationsacrossERFCand
UKBiobank.Forexample,1-SDhighersystolicbloodpressurewas
notassociatedwith riskofVTE inERFC(HR, 1.07;95%CI,0.95-
1.19)butwas inverselyassociatedwithriskofVTEinUKBiobank
(HR,0.83;95%CI,0.77-0.90).Conversely, 1-SDhigherdiastolic
blood pressurewas associatedwith higher risk of VTE in ERFC
(HR, 1.26; 95%CI, 1.11-1.42) butwas not associatedwith risk of
VTE in UK Biobank (HR, 0.94; 95% CI, 0.87-1.02). In ERFC,
history of diabeteswas associatedwithhigher risk ofVTE (HR,
1.69; 95%CI, 1.33-2.16) aswas 1-SD higher fasting baseline glu-
cose concentration (HR, 1.27; 95% CI, 1.08-1.48), while in UK
Biobank, history of diabeteswas inversely associatedwith risk
of VTE (HR, 0.83; 95% CI, 0.69-0.99). To investigate whether
thesediscordantassociationschiefly reflectedthedifferentVTE
outcomes recordedacrossERFCandUKBiobank,we restricted
analysis to theUKBiobank (which had recorded both fatal and
nonfatal VTE outcomes). In UK Biobank–specific analyses, we
foundasimilarpatternofdifferenceofHRs for fatal vsnonfatal
VTEswith blood pressure and diabetes to that observed in our
comparison across ERFC and UK Biobank (eFigure 2 in the
Supplement). This result suggests that bloodpressure anddia-
betesmayhavedifferingassociationswithfatalvsnonfatalVTEs.
At the timeofouranalysis,dataonplasmabiomarkerswere
available in the ERFC but not in UK Biobank (Figure 2). In the
ERFC,apolipoproteinB,apolipoproteinA,andlipoprotein(a) lev-
els each showed suggestively inverse associations with risk of
VTE, whereas triglyceride, non–high-density lipoprotein cho-
lesterol, and high-density lipoprotein cholesterol levels each
showednoassociations.Fastingglucose,C-reactiveprotein,and
fibrinogen levels were each associatedwith higher risk of VTE.
Inanalyses comparingPEwithDVT,higherBMIandhigher
waist circumference had stronger associations with PE than
DVT (Figure 3). Further analyses that subcategorizedVTEout-
comes as provoked vs unprovoked in UK Biobank did not
reveal major differences in the associations of most CVD risk
factors, with the exceptions of older age and male sex
(Figure 4).
In analyses comparing VTEwith CHD outcomes, associa-
tionswere stronger for CHD in both ERFC andUKBiobank for
most risk factors, including age, male sex, current smoking
status, history of diabetes, higher systolic and diastolic blood
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pressure, and proatherogenic lipid levels (eFigures 3 and 4 in
the Supplement). In contrast, higher BMI and waist circum-
ference had somewhat stronger associations with VTE com-
pared with CHD, whereas circulating inflammatory markers
were associated with both conditions to a broadly similar ex-
tent (eFigures 3 and 4 in the Supplement). Findings were
broadly similar in sensitivity analyses that did not adjust for
BMI (eTable 2 in the Supplement), excludedparticipantswith
historyof cancerdiagnosis atbaseline (eFigure5 in theSupple-
ment), censored for first CVDevents in ERFC (eFigure 6 in the
Supplement), and used baseline levels of risk factors, except
for the expected decrease in the magnitudes of association
when not correcting for within-person variability in the con-
tinuous variables (eFigures 7-9 in the Supplement).
Discussion
In this analysis of individual-level data on several estab-
lished cardiovascular risk factors from more than 1.1 million
Table. Summary of Baseline Characteristics and Outcomes Recorded
Characteristic
ERFC UK Biobanka
No. of
Cohorts No. Measure No. Measure
Demographic and lifestyle factors, No. (%)
Age at baseline survey, mean (SD), y 75 731 728 51.9 (9.0) 421 537 56.4 (8.1)
Male 70 731 728 328 332 (44.9) 421 537 187 838 (44.6)
Current smoker 75 731 728 222 016 (30.3) 421 537 43 847 (10.4)
History of diabetes 74 731 728 25 982 (3.6) 421 537 17 622 (4.2)
Current alcohol drinker 58 386 831 271 499 (70.2) 421 197 389 507 (92.5)
Anthropometric and physical markers,
mean (SD)
Systolic blood pressure, mm Hg 73 566 724 131 (19) 421 179 137 (19)
Diastolic blood pressure, mm Hg 72 565 895 80.0 (10.9) 421 181 82.2 (10.1)
Body mass indexb 75 731 728 25.4 (4.2) 421 537 27.2 (4.7)
Waist-to-hip ratio 34 264 787 0.85 (0.08) 421 440 0.87 (0.09)
Waist circumference, cm 36 265 465 87.6 (12.5) 421 464 89.6 (13.2)
Lipid-related markers, mean (SD)
Total cholesterol levels, mg/dL 68 455 177 222.0 (43.6) NA NA
Non-HDL cholesterol levels, mg/dL 57 311 888 171.0 (44.8) NA NA
HDL cholesterol levels, mg/dL 57 312 207 52.9 (14.7) NA NA
Log triglyceride levels, mg/dLc 56 322 096 4.79 (0.53) NA NA
Apolipoprotein B levels, mg/dL 20 80 712 103 (29) NA NA
Apolipoprotein A1 levels, mg/dL 20 84 483 137 (33) NA NA
Log Lp(a) levels, mg/dLd 18 66 382 2.20 (1.20) NA NA
Metabolic and inflammatory markers,
mean (SD)
Fasting glucose levels, mg/dL 33 130 322 88.5 (24.3) NA NA
Log CRP levels, mg/Le 28 70 855 0.46 (1.07) NA NA
Fibrinogen levels, mg/dL 29 115 002 241.2 (68.7) NA NA
Albumin levels, g/dL 25 115 309 4.29 (0.39) NA NA
Study period, median (5th centile-95th
centile)f
Baseline survey year 75 731 728 1986
(1971-2000)
421 537 2009
(2007-2010)
Latest follow-up year 75 731 728 2004
(1989-2011)
421 537 2016
(2016-2016)
Outcomes, No.
Time to event or censoring, median (5th
centile-95th centile), y
75 731 728 15.4 (5.5-32.0) 421 537 6.1 (4.8-7.5)
Total follow up, person-years in millions 75 731 728 12.807 421 537 2.566
Non-fatal MI NAg NA NA 421 537 2808
Fatal CHD 75 731 728 25 131 421 537 577
VTE 75 731 728 1041 421 537 2321
Nonfatal VTE NAg NA NA 421 537 2234
Fatal VTE 75 731 728 1041 421 537 87
Pulmonary embolism 75 731 728 855 421 537 1273
Deep venous thromboembolism 75 731 728 186 421 537 1048
Unprovoked VTE NA NA NA 421 537 1465
Provoked VTE NA NA NA 421 537 856
Abbreviations: CHD, coronary heart
disease; CRP, C-reactive protein;
ERFC, Emerging Risk Factors
Collaboration; HDL, high-density
lipoprotein; Lp(a), lipoprotein(a);
MI, myocardial infarction; NA, not
applicable; PE, pulmonary embolism;
VTE, venous thromboembolism.
SI conversion factor: To convert
cholesterol to millimoles per liter,
multiply by 0.0259; triglycerides to
millimoles per liter, multiply by
0.0113; apolipoprotein to grams per
liter, multiply by 0.01; Lp(a) to
micromoles per liter, multiply by
0.0357; fasting glucose to
micromoles per liter, multiply by
0.0555; CRP to nanomoles per liter,
multiply by 9.524; fibrinogen to grams
per liter,multiply by0.01; and albumin
to grams per liter,multiply by 10.
a At the time of these analyses, data
on plasma biomarkers were not
available in UK Biobank.
bBodymass index calculated as
weight in kilograms divided by
height in meters squared.
c Median (interquartile range)
triglyceride level was 117 (82-170)
mg/dL.
dMedian (interquartile range) Lp(a)
level was 9 (4-25) mg/dL.
e Median (interquartile range) CRP
level was 1.48 (0.72-3.15) mg/dL.
f Follow-up and outcome summaries
among participants with complete
data on age, sex, smoking status,
history of diabetes, and bodymass
index.
gMost of the studies in ERFC did not
ascertain nonfatal VTE outcomes;
hence, analyses in ERFCwere
restricted to comparison of fatal
CHD outcomes only.
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participants in 76 cohorts, we found that older age, smoking,
and higher levels of adiposity were clearly associated with
higher risk of VTE. These findings suggest that there is
overlap in at least some major population determinants of
important venous and arterial thrombotic diseases.
Our study characterized dose-response associations
between several clinical measures of adiposity (eg, waist cir-
cumference and BMI) and VTE risk and showed no evidence
of a thresholdbelowwhich leaner bodyhabitus stoppedbeing
associatedwith lowerVTErisk.Theassociationofobesitywith
VTE is supported by previous mendelian randomization
studies of genetic variants associated with increased adipos-
ity, which are also associated with increased risk of VTE.33,34
Furthermore, we found that associations of BMI and waist
circumference were somewhat stronger with PE vs DVT
and about twice as strong with VTE vs CHD. These data sug-
gest that efforts to combat the entire spectrum of obesity
and overweight should yield important benefits for VTE
prevention.
As regards risk behaviors, our study confirmed theknown
association of current smokingwith risk of VTE.9,13 This asso-
ciationwas similar inmagnitude forPEandDVToutcomesbut
weaker than thatobserved forCHD.Previous studieshave sug-
gested thatmuch of the excess risk of VTE in smokerswas be-
cause of increased hospitalization for smoking-related dis-
eases, includingcancer.35,36However, inouranalysis, smoking
was similarly associated with both provoked and unpro-
voked VTE; furthermore, HRs did not change appreciably
Figure 1. Hazard Ratios (HRs) for Venous Thromboembolism (VTE) by 10-Year Age Groups and Fifths of Continuous Factors
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after exclusion of participants with history of cancer diagno-
sis at baseline. We also noted a pattern of association be-
tween alcohol consumption and VTE similar to that reported
inprevious studies of alcohol consumptionandnonfatalmyo-
cardial infarction.32,37,38 (Bycontrast, alcohol consumptionhas
previously been positively associatedwith risks of fatal coro-
narydisease, stroke,andheart failure.)Althoughpreviousstud-
ies have reported thatmoderate alcohol consumption is asso-
ciatedwith lower levels of hemostatic factors (eg, fibrinogen,
factorVII, andvonWillebrand factor),39,40 further studies are
needed to determine whether moderate alcohol consump-
tion has a causal role in VTE.
Figure 2. Hazard Ratios (HRs) for Venous Thromboembolism (VTE) for Established Cardiovascular Risk Factors
HR (95% CI) per 1-SD Higher
or Contrasta
1 2 40.5
Risk Factor No.
No. of
Events
HR
(95% CI)
Association
P Value
Age (per decade)
UK Biobank
ERFC
421 537
731 728
2321
1041
1.81 (1.71-1.92)
2.67 (2.45-2.91)
<.001
<.001
Sex (male vs female)
UK Biobank
ERFC
421 537
731 728
2321
1041
1.44 (1.32-1.56)
1.17 (0.998-1.38)
<.001
.053
Smoking (current vs other)
UK Biobank
ERFC
421 537
731 728
2321
1041
1.23 (1.08-1.40)
1.38 (1.20-1.58)
.002
<.001
Diabetes (yes vs no)
UK Biobank
ERFC
421 537
731 728
2321
1041
0.83 (0.69-0.99)
1.69 (1.33-2.16)
.04
<.001
Alcohol consumption (current vs other)
UK Biobank
ERFC
421 197
386 831
2319
564
0.82 (0.71-0.94)
0.75 (0.61-0.93)
.006
.01
Systolic blood pressure
UK Biobank
ERFC
421 179
566 724
2315
887
0.83 (0.77-0.90)
1.07 (0.95-1.19)
<.001
.28
Diastolic blood pressure
UK Biobank
ERFC
421 181
565 895
2315
885
0.94 (0.87-1.02)
1.26 (1.11-1.42)
.15
<.001
BMI
UK Biobank
ERFC
421 537
731 728
2321
1041
1.37 (1.32-1.41)
1.43 (1.35-1.50)
<.001
<.001
Waist-to-hip ratio
UK Biobank
ERFC
421 440
264 787
2319
329
1.52 (1.40-1.65)
1.23 (1.05-1.45)
<.001
.01
Waist circumference
UK Biobank
ERFC
421 464
265 465
2320
333
1.60 (1.52-1.68)
1.54 (1.37-1.73)
<.001
<.001
Non-HDL cholesterol levels
ERFC 311 888 440 0.88 (0.76-1.03) .11
HDL cholesterol levels
ERFC 312 207 440 1.09 (0.94-1.26) .27
Log triglycerides levels
ERFC 322096 537 0.95 (0.81-1.11) .49
Apolipoprotein B levels
ERFC 80 712 261 0.76 (0.61-0.94) .01
Apolipoprotein A1 levels
ERFC 84 483 265 0.65 (0.47-0.88) .006
Log Lp(a)
ERFC 66 382 210 0.83 (0.71-0.98) .03
Fasting glucose levels
ERFC 130 322 323 1.27 (1.08-1.48) .003
Log CRP
ERFC 70 855 231 1.71 (1.33-2.20) <.001
Fibrinogen levels
ERFC 115 002 223 1.37 (1.11-1.68) .003
Albumin levels
ERFC 115 309 367 0.75 (0.56-1.02) .07
All comparisons were adjusted for
age, sex, smoking status, history of
diabetes, and usual bodymass index
(BMI) (waist-to-hip ratio and waist
circumference were not adjusted for
usual BMI). Associations involve
Emerging Risk Factors Collaboration
(ERFC) data for fatal VTE and UK
Biobank data for VTE. CRP indicates
C-reactive protein; HDL, high-density
lipoprotein; Lp(a), lipoprotein(a).
a Hazard ratios are presented per 1-SD
higher usual risk factor level unless
otherwise indicated.
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Ourstudy identifiedpotentially inverseassociationsofpro-
atherogenic lipid levelswithVTE. For example, apolipoprotein
Band lipoprotein(a) levelswereeachassociatedwith lower risk
of VTE, a finding that awaits further elucidation.41 Proinflam-
matory soluble biomarkers (eg, C-reactive protein) were posi-
tively associated with VTE, a finding consistent with the asso-
ciations we observed for CHD outcomes. Although previous
mendelianrandomizationstudiessuggest thatCRPandfibrino-
genlevelsareunlikelytobedirectcausal factors inCHD,42,43such
genetic epidemiological data are sparser in relation to VTE.
It is not clear why our study found inconsistent associa-
tions of blood pressure and history of diabetes with VTE out-
comes across UKBiobank and the ERFC. One potential expla-
nation is that thesedatasources recordedmostlydifferingtypes
ofVTEoutcomes, ie,UKBiobank involvedmostlynonfatalout-
comes whereas ERFC involved only fatal outcomes. Our ex-
ploratory analysis ofUKBiobankdatawas consistentwith this
explanation, as it found differing results with blood pressure
anddiabetes for fatal VTEvsnonfatal VTE similar to those ob-
served in comparisons acrossUKBiobankand theERFC.How-
ever, futurestudieswithmoredetailedclinical informationwill
beneededtounderstandthesepossibledifferenceswithgreater
confidence.
Strengths and Limitations
Ourstudyhadmajor strengths. It avoided the limitationsof ret-
rospectivecase-control studydesignsbyanalyzingprospective
cohort data onmore than 1.1million participantswithout CVD
at baseline. Access to individual participant data avoided the
limitations of literature-basedmeta-analyses. It also enabled a
commonapproachtoadjustment forpotential confoundingfac-
tors, time-to-event analyses, correction for regressiondilution
bias, and head-to-head comparisons of VTE and CHD. We ex-
plored idiopathicVTEvsVTEprovokedbyestablished risk fac-
tors (suchascancerorprolonged immobility), albeitusingprag-
matic record-based definitions.44 The generalizability of our
resultswas enhanced by inclusion of data from 75 prospective
studies inERFCrecruited from1960 through2008 in 18differ-
ent countries. Toenhancepower andevaluate the relevanceof
findings to the contemporary situation,we includeddata from
UKBiobank,which recruited participants from2006 to 2010.
Our study also had limitations.We did not routinely have
information inERFCdata onnon-CVD risk factors forVTE (eg,
oral contraception use) or medication use (eg, anticoagu-
lants).Misclassificationofdiseaseoutcomes couldhavearisen
from inaccuracies inhospital discharge records anddeath cer-
tificates,diluting thestrengthof theobservedassociations.45-47
Figure 3. Hazard Ratios (HRs) for Pulmonary Embolism (PE) vs Deep Vein Thrombosis (DVT)
for Established Cardiovascular Risk Factors in UK Biobank
HR (95% CI) per 1-SD Higher
or Contrasta
1 2 40.5
Risk Factor No.
No. of
Events
HR
(95% CI)
Difference
P Value
Age (per decade)
PE
DVT
421 537
421 537
1273
1048
1.91 (1.76-2.06)
1.70 (1.57-1.85)
.051
Sex (male vs female)
PE
DVT
421 537
421 537
1273
1048
1.37 (1.23-1.54)
1.52 (1.34-1.72)
.24
Smoking (current vs other)
PE
DVT
421 537
421 537
1273
1048
1.29 (1.09-1.53)
1.16 (0.95-1.40)
.40
Diabetes (yes vs no)
PE
DVT
421 537
421 537
1273
1048
0.74 (0.57-0.95)
0.94 (0.72-1.23)
.20
Alcohol consumption (current vs other)
PE
DVT
421 197
421 197
1272
1047
0.90 (0.74-1.10)
0.73 (0.60-0.90)
.15
Systolic blood pressure
PE
DVT
421 179
421 179
1268
1047
0.78 (0.70-0.86)
0.91 (0.81-1.02)
.046
Diastolic blood pressure
PE
DVT
421 181
421 181
1268
1047
0.96 (0.86-1.07)
0.92 (0.81-1.04)
.60
BMI
PE
DVT
421 537
421 537
1273
1048
1.44 (1.38-1.50)
1.28 (1.21-1.35)
.001
Waist-to-hip ratio
PE
DVT
421 440
421 440
1272
1047
1.67 (1.50-1.85)
1.35 (1.20-1.53)
.01
Waist circumference
PE
DVT
421 464
421 464
1273
1047
1.74 (1.63-1.86)
1.43 (1.33-1.54)
<.001
All comparisons were adjusted for
age, sex, smoking status, history of
diabetes, and usual bodymass index
(BMI) (waist-to-hip ratio and waist
circumference were not adjusted for
usual BMI). Associations involve UK
Biobank data only.
a Hazard ratios are presented per 1-SD
higher usual risk factor level unless
otherwise indicated.
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However, 2 observations argue againstmajor diseasemisclas-
sification inour study. First,weobservedassociationsofmea-
sures of adiposity with VTE risk similar in size to those previ-
ously reported in much smaller studies based on detailed
validation of VTE events.6 Second,we observed directionally
opposite associations of proatherogenic lipid levels with VTE
and CHD outcomes despite the 2 conditions having similar
clinical presentations.
Conclusions
Among a panel of several established cardiovascular risk fac-
tors, older age, smoking, and adiposity were consistently as-
sociatedwithhigherVTE risk. There is overlap in at least some
of themajorpopulationdeterminantsof importantvenousand
arterial thrombotic diseases.
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HR (95% CI) per 1-SD Higher
or Contrasta
1 2 40.5
Risk Factor No.
No. of
Events
HR
(95% CI)
Difference
P Value
Age (per decade)
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
1.68 (1.57-1.80)
2.07 (1.88-2.28)
.001
Sex (male vs female)
Unprovoked VTE
Provoked VTE
421537
421 537
1465
856
1.62 (1.46-1.79)
1.18 (1.03-1.35)
<.001
Smoking (current vs other)
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
1.23 (1.05-1.45)
1.22 (0.98-1.51)
.91
Diabetes (yes vs no)
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
0.78 (0.62-0.99)
0.91 (0.68-1.22)
.44
Alcohol consumption (current vs other)
Unprovoked VTE
Provoked VTE
421 197
421 197
1465
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0.83 (0.69-0.99)
0.81 (0.64-1.02)
.89
Systolic blood pressure
Unprovoked VTE
Provoked VTE
421 179
421 179
1460
855
0.86 (0.78-0.95)
0.79 (0.69-0.90)
.28
Diastolic blood pressure
Unprovoked VTE
Provoked VTE
421 181
421 181
1460
855
1.01 (0.91-1.12)
0.83 (0.73-0.95)
.02
BMI
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
1.40 (1.34-1.46)
1.31 (1.24-1.39)
.08
Waist-to-hip ratio
Unprovoked VTE
Provoked VTE
421 440
421 440
1464
855
1.58 (1.43-1.75)
1.42 (1.24-1.63)
.21
Waist circumference
Unprovoked VTE
Provoked VTE
421 464
421 464
1465
855
1.67 (1.58-1.78)
1.47 (1.35-1.60)
.01
All comparisons were adjusted for
age, sex, smoking status, history of
diabetes, and usual bodymass index
(BMI) (waist-to-hip ratio and waist
circumference were not adjusted for
usual BMI). Associations involve UK
Biobank data only.
a Hazard ratios are presented per 1-SD
higher usual risk factor level unless
otherwise indicated.
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